Edition:
United Kingdom

Innoviva Inc (INVA.OQ)

INVA.OQ on NASDAQ Stock Exchange Global Select Market

16.44USD
8:59pm GMT
Change (% chg)

$-0.30 (-1.79%)
Prev Close
$16.74
Open
$16.72
Day's High
$16.85
Day's Low
$16.33
Volume
267,589
Avg. Vol
269,981
52-wk High
$17.21
52-wk Low
$11.06

Chart for

About

Innoviva, Inc., formerly Theravance, Inc., is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium... (more)

Overall

Beta: 2.58
Market Cap(Mil.): $1,566.05
Shares Outstanding(Mil.): 109.36
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.60
EPS (TTM): -- -- --
ROI: -- 14.90 10.66
ROE: -- 16.41 14.30

BRIEF-Sarissa Capital Reconstitutes Innoviva Board

* JULES HAIMOVITZ, SARAH SCHLESINGER, AND MARK DIPAOLO WILL BE ADDED TO INNOVIVA BOARD Source text for Eikon:

13 Feb 2018

BRIEF-Innoviva Enteres Into Agreement With Sarissa Capital Management

* INNOVIVA INC - ENTERED INTO AN AGREEMENT WITH SARISSA CAPITAL MANAGEMENT LP, AND CERTAIN OF ITS AFFILIATES

13 Feb 2018

Drug company Innoviva settles with activist hedge fund Sarissa: sources

U.S. respiratory drug company Innoviva Inc has reached a settlement with activist hedge fund Sarissa Capital Management LP to replace its board of directors and remove the threat of a new proxy contest, people familiar with the matter said on Monday.

13 Feb 2018

Drug company Innoviva settles with activist hedge fund Sarissa -sources

Feb 12 U.S. respiratory drug company Innoviva Inc has reached a settlement with activist hedge fund Sarissa Capital Management LP to replace its board of directors and remove the threat of a new proxy contest, people familiar with the matter said on Monday.

13 Feb 2018

BRIEF-Innoviva Reports Q4 Adj Earnings Per Share $0.55

* INNOVIVA REPORTS RECORD FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

08 Feb 2018

BRIEF-Innoviva Appoints Eric D'Esparbes As Co's Interim Principal Executive Officer

* INNOVIVA SAYS ON FEB 7, CO ANNOUNCED APPOINTMENT OF ERIC D'ESPARBES AS CO'S INTERIM PRINCIPAL EXECUTIVE OFFICER, EFFECTIVE FEB 6 - SEC FILING

07 Feb 2018

AstraZeneca's three-in-one inhaler helps COPD patients in trial

AstraZeneca said an inhaler for chronic obstructive pulmonary disease (COPD) delivered improved lung function in a late stage trial that could challenge GlaxoSmithKline's new three-in-one inhaler.

26 Jan 2018

UPDATE 1-AstraZeneca's 3-in-1 inhaler helps COPD patients in trial

Jan 26 AstraZeneca said an inhaler for chronic obstructive pulmonary disease (COPD) delivered improved lung function in a late stage trial that could challenge GlaxoSmithKline's new three-in-one inhaler.

26 Jan 2018

BRIEF-GSK and Innoviva announce positive data from COPD study

* GSK STUDY DEMONSTRATES SUPERIORITY OF ANORO ELLIPTA TO STIOLTO RESPIMAT IN IMPROVING LUNG FUNCTION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE

01 Nov 2017

BRIEF-Innoviva reports Q3 adj earnings $0.31/shr

* Innoviva reports third quarter 2017 financial results and provides business updates

25 Oct 2017

Earnings vs. Estimates